Biweekly GLP-1 Drug Clears First Human Test via Dual Fatty Acid Engineering
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Wed, 5 August 2026
What it is about
Novo Nordisk WegovyHsing-Mao ChuTse-Wen ChangAmgen MaritideChien-Jen ChenAmerican Diabetes AssociationOffice Of ManagementPfizerCapital GroupT-E Pharma HoldingInternational Journal Of PharmaceuticsDepartment Of War SectionView ResearchWorld CongressNovartisGenentechCenter LaboratoriesUs Department Of WarValenciennes Hospital Centre Centre Hospitalier De ValenciennesNational Defense Authorization
Who published it, and when
How it spread - 1 original report
Wed, 5 August 2026
1 report- techtimes.com13:01first to report
Long-acting GLP-1 drug TE-8105, developed by Taiwan biotech Immunwork, confirmed a five-day plasma half-life in first-in-human trials using a dual fatty acid bundle approach not used by any approved GLP-1 drug, supporting biweekly obesity injections and positioning Immunwork alongside Pfizer in the